ASX:CDY Cellmid (CDY) Stock Price, News & Analysis → War Over Taiwan? Protect Your Wealth NOW (From Behind the Markets) (Ad) Free CDY Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Cellmid alerts: Email Address Ad Behind the MarketsWar Over Taiwan? Protect Your Wealth NOWWith tensions rapidly escalating, Taiwan could provide the spark at any moment. Don't let your financial future get caught in the crossfire unprepared.Access my report now >>> About CellmidCellmid Limited, a life sciences company, researches, develops, and commercializes diagnostic and therapeutic products for cancer and various chronic inflammatory conditions in Australia, the United States, and Japan. The company offers midkine, a driver and modulator of inflammatory diseases, including chronic inflammatory diseases and cancer; and focuses on blocking midkine, a protein for autoimmune disorders, chronic inflammation, osteoporosis, cardiovascular diseases, cancer, and neurodegenerative diseases. It also develops and sells over-the-counter products; and a range of FGF5 inhibitor hair growth products under the evolis, evolis Professional, Lexilis Hybrid, Jo-Ju RED, and Lexilis BLACK brands. In addition, the company sells SARS-CoV-2 antibody kits and PCR tests. It markets its products through retailers and wholesalers, as well as through a direct-to-consumer e-commerce platform. Cellmid Limited was incorporated in 2004 and is based in Sydney, Australia.Read More Ad Behind the MarketsWar Over Taiwan? Protect Your Wealth NOWWith tensions rapidly escalating, Taiwan could provide the spark at any moment. Don't let your financial future get caught in the crossfire unprepared.Access my report now >>> CDY Stock News HeadlinesMay 6, 2023 | marketwatch.comCovid-19 Rapid Diagnostic Test market research report of the pertinent information about this industry with forecasted CAGR 5.4% from 2023-2030May 6, 2023 | marketwatch.comCovid-19 Rapid Diagnostic Test Market: Trends, Recent Growth till 2030April 26, 2024 | Behind the Markets (Ad)War Over Taiwan? Protect Your Wealth NOWWith tensions rapidly escalating, Taiwan could provide the spark at any moment. Don't let your financial future get caught in the crossfire unprepared.April 9, 2023 | marketwatch.com2023, Alopecia (Hair Loss Treatment) Market to Eyewitness Massive Growth by 2030March 29, 2023 | marketwatch.comHair Loss Products Market SWOT Analysis till 2030September 29, 2022 | finance.yahoo.comEastspring Investments - Japan Dynamic Fund - CDY (0P00016DXV)October 27, 2021 | msn.comReporting Season Round Up: Eclectic investment firm HGL led the pack in morning tradeSee More Headlines Receive CDY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cellmid and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/21/2019Today4/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:CDY CUSIPN/A CIKN/A Webwww.cellmid.com.au Phone61 2 9221 6830FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio13.74 Current Ratio5.89 Quick Ratio4.45 Sales & Book Value Annual Sales$5.82 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow4.63 Book ValueA$0.06 per share Price / BookN/AMiscellaneous Outstanding Shares220,216,992Free FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMs. Maria HalaszCEO, MD & Exec. DirectorMr. Koichiro Koike (Age 64)Managing Director of Advangen Inc Comp: $303.67kMr. Matthew DudekGroup Financial ControllerMr. Dominic BurgChief Operating OfficerDr. Graham RobertsonHead of R&DMs. Trish FrelanGlobal Head of Marketing Advangen Pty LtdMr. Lee Tamplin B.A.Company Sec.More ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All Competitors CDY Stock Analysis - Frequently Asked Questions How were Cellmid's earnings last quarter? Cellmid Limited (ASX:CDY) issued its earnings results on Thursday, February, 21st. The company reported ($0.05) earnings per share for the quarter. What other stocks do shareholders of Cellmid own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cellmid investors own include Westgold Resources (WGX) and Credit Intelligence (CI1). This page (ASX:CDY) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupTrump is sounding the alarmPreserve Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellmid Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
